Jefferies reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM), and raised the price target to $22.00 (from $20.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Bellicum Pharma (BLCM): Raising PT On Accelerated BPX-501 Approval - Piper JaffrayAugust 9, 2016 9:11 AM Citi Upgrades Bellicum Pharmaceuticals (BLCM) to BuyAugust 9, 2016 7:33 AM Bellicum Pharma (BLCM) Misses Q2 EPS by 4cAugust 8, 2016 5:06 PM Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate UpdateAugust 8, 2016 4:05 PM Trading Radar for 8/8: Nuance (NUAN), LendingClub (LC), Tyson Foods (TSN), Twilio (TWLO), Hertz (HTZ) ReportAugust 5, 2016 2:53 PM